The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
Discover 7 surprising ways asthma develops in adulthood – from workplace exposures to hormonal shifts. Frequently begins ...
A groundbreaking consensus report on anaphylaxis – the severe reaction some people experience from bee stings, peanut butter ...
In this randomized, placebo-controlled replicate trial, depemokimab decreased the annual rate of exacerbations among patients ...
An asthma attack can come on suddenly or as a gradual worsening of symptoms. Here are the key signs you may be experiencing ...
Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.This cross-sectional cohort ...
US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...
In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...
2d
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.
The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...
Professor David Denning evaluates timely and accurate diagnosis of Aspergillus infection and the clinical spectrum of ...
The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback